TY - JOUR
T1 - The effect of atorvastatin on serum lipide, lipoproteins and NMR-spectroscopy defined lipoprotein subclasses in type 2 diabetic patients with ischaemic heart disease
AU - Soedamah-Muthu, S.S.
AU - Colhoun, H.M.
AU - Thomason, M.J.
AU - Betteridge, D.J.
AU - Durrington, P.N.
AU - Hitman, G.A.
AU - Fuller, J.H.
AU - Julier, K.
AU - Mackness, M.I.
AU - Neil, H.A.W.
PY - 2003
Y1 - 2003
N2 - The effect of statin therapy on subclasses of LDL, VLDL and HDL lipoproteins is unclear. We compared changes in serum lipids, apolipoproteins and nuclear magnetic resonance (NMR) spectroscopy measured lipoprotein subclass concentration and average particle size over a minimum 6 months treatment period of atorvastatin 10 mg vs. placebo in 122 men and women. All subjects had type 2 diabetes and a modest dyslipidaemia (mean LDL-cholesterol 3.2 mmol/l and median triglycerides 1.8 mmol/l) and had a previous myocardial infarction. Compared with placebo, atorvastatin therapy was associated with a greater decrease in medium VLDL (median within person change -13.4 vs. -5.9 nmol/l, P
AB - The effect of statin therapy on subclasses of LDL, VLDL and HDL lipoproteins is unclear. We compared changes in serum lipids, apolipoproteins and nuclear magnetic resonance (NMR) spectroscopy measured lipoprotein subclass concentration and average particle size over a minimum 6 months treatment period of atorvastatin 10 mg vs. placebo in 122 men and women. All subjects had type 2 diabetes and a modest dyslipidaemia (mean LDL-cholesterol 3.2 mmol/l and median triglycerides 1.8 mmol/l) and had a previous myocardial infarction. Compared with placebo, atorvastatin therapy was associated with a greater decrease in medium VLDL (median within person change -13.4 vs. -5.9 nmol/l, P
KW - familial combined hyperlipidemia
KW - cholesteryl ester transfer
KW - b-containing lipoproteins
KW - coronary-artery-disease
KW - triglyceride-rich lipoproteins
KW - low-density lipoproteins
KW - coa reductase inhibitor
KW - simvastatin treatment
KW - pravastatin treatment
KW - subfraction
U2 - 10.1016/S0021-9150(02)00428-8
DO - 10.1016/S0021-9150(02)00428-8
M3 - Article
SN - 0021-9150
VL - 167
SP - 243
EP - 255
JO - Atherosclerosis
JF - Atherosclerosis
IS - 2
ER -
